1 active not recruiting, 1 recruiting. 2 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 2 | Active not recruiting 1, Recruiting 1 |
Follow Lee011: new trials by email Literature Review of Lee011 trials Research Report on Lee011
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Roll-over Study to Allow Continued Access to Ribociclib Ribociclib, Letrozole, Anastrozole - Metastatic Breast Cancer | Phase 4 | Active not recruiting | Novartis Pharmaceuticals | 134 | 2022-07-07 | 2026-10-19 |
| The FLOTILLA Study: Providing Continued Access to The Study Medicines Encorafenib and Binimetinib for Participants in Prior Clinical Trials Binimetinib, Encorafenib, Vemurafenib - Solid Tumors | Phase 4 | Recruiting | Pfizer | 210 | 2022-07-05 | 2026-10-19 |
Breast Neoplasms (1)
Novartis Pharmaceuticals (1) · Pfizer (1)
Brazil (2) · Greece (2) · Italy (2) · Portugal (2) · South Korea (2) · Spain (2) · Turkey (Türkiye) (2) · United States (2) · Argentina (1) · Australia (1) · Canada (1) · China (1) · Costa Rica (1) · Czechia (1) · France (1)
2023 (1)